Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of surgical variables on residual glandular tissue in risk-reducing mastectomies: Results of a retrospective monocentric study from a center of the German consortium for hereditary breast and ovarian cancer.
Mohrmann S, Kolberg L, Jäger B, Hoffmann J, Nestle-Krämling C, Zwiefel K, Friebe V, Sawicki LM, Bruckmann NM, Jannusch K, Morawitz J, Antoch G, Fehm TN, Kirchner J, Dietzel F. Mohrmann S, et al. Eur J Surg Oncol. 2023 Nov;49(11):107031. doi: 10.1016/j.ejso.2023.107031. Epub 2023 Aug 24. Eur J Surg Oncol. 2023. PMID: 37683424
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ. Reichardt P, et al. Among authors: mohrmann s. Ann Oncol. 2003 Aug;14(8):1227-33. doi: 10.1093/annonc/mdg346. Ann Oncol. 2003. PMID: 12881384 Free article. Clinical Trial.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A. Erber R, et al. Among authors: mohrmann s. Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28. Breast Cancer Res Treat. 2015. PMID: 25721604 Clinical Trial.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F. Schouten PC, et al. Among authors: mohrmann s. Int J Cancer. 2016 Aug 15;139(4):882-9. doi: 10.1002/ijc.30078. Epub 2016 May 5. Int J Cancer. 2016. PMID: 26946057 Clinical Trial.
An unusual case of advanced bilateral male breast cancer.
Bauerschmitz GJ, Karan D, Zwiefel K, Bender HG, Mohrmann S. Bauerschmitz GJ, et al. Among authors: mohrmann s. Onkologie. 2008 Oct;31(10):542-4. doi: 10.1159/000151623. Epub 2008 Sep 23. Onkologie. 2008. PMID: 18854654
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Mutschler NS, Scholz C, Friedl TWP, Zwingers T, Fasching PA, Beckmann MW, Fehm T, Mohrmann S, Salmen J, Ziegler C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Jückstock J, Janni W, Rack B. Mutschler NS, et al. Among authors: mohrmann s. Clin Breast Cancer. 2018 Apr;18(2):175-183. doi: 10.1016/j.clbc.2018.01.008. Epub 2018 Jan 31. Clin Breast Cancer. 2018. PMID: 29598955 Clinical Trial.
61 results